Trump Administration Wont Join Global Effort For COVID-19 Vaccine | HuffPost Latest News - Action News
Home WebMail Monday, November 4, 2024, 10:32 PM | Calgary | 4.4°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Posted: 2020-09-01T23:12:40Z | Updated: 2020-09-01T23:12:40Z

WASHINGTON (AP) The Trump administration said Tuesday that it will not work with an international cooperative effort to develop and distribute a COVID-19 vaccine because it does not want to be constrained by multilateral groups like the World Health Organization.

The decision to go it alone, first reported by The Washington Post, follows the White Houses decision in early July to pull the United States out of the WHO . Trump claims the WHO is in need of reform and is heavily influenced by China.

Some nations have worked directly to secure supplies of vaccine, but others are pooling efforts to ensure success against a disease that has no geographical boundaries. More than 150 countries are setting up the COVID-19 Vaccines Global Access Facility, or COVAX.

That cooperative effort, linked with the WHO, would allow nations to take advantage of a portfolio of potential vaccines to ensure their citizens are quickly covered by whichever ones are deemed effective. The WHO says even governments making deals with individual vaccine makers would benefit from joining COVAX because it would provide backup vaccines in case the ones being made through bilateral deals with manufacturers arent successful.

The United States will continue to engage our international partners to ensure we defeat this virus , but we will not be constrained by multilateral organizations influenced by the corrupt World Health Organization and China, said White House spokesman Judd Deere. This president will spare no expense to ensure that any new vaccine maintains our own Food and Drug Administrations gold standard for safety and efficacy, is thoroughly tested and saves lives.

Rep. Ami Bera, D-Calif., said the administrations decision was shortsighted and will hamper the battle to end the pandemic.

Joining COVAX is a simple measure to guarantee U.S. access to a vaccine no matter who develops it first, tweeted Bera, a medical doctor. This go-it-alone approach leaves America at risk of not getting a vaccine.

The administrations decision, paired with the U.S. withdrawal from the WHO, means the U.S. is abdicating Americas global leadership in fighting pandemics, according to Tom Hart, North America director at The ONE Campaign, an advocacy organization co-founded by Bono of the rock band U2.

Not only does this move put the lives of millions around the world at risk, it could completely isolate Americans from an effective vaccine against COVID-19, Hart said.

A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they really work.

Your Support Has Never Been More Critical

Other news outlets have retreated behind paywalls. At HuffPost, we believe journalism should be free for everyone.

Would you help us provide essential information to our readers during this critical time? We can't do it without you.

You've supported HuffPost before, and we'll be honest we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you.

Whether you give once or many more times, we appreciate your contribution to keeping our journalism free for all.

You've supported HuffPost before, and we'll be honest we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you.

Whether you give just one more time or sign up again to contribute regularly, we appreciate you playing a part in keeping our journalism free for all.

Support HuffPost

AstraZeneca announced Monday its vaccine candidate has entered the final testing stage in the U.S. The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.

Two other vaccine candidates began final testing this summer in tens of thousands of people in the U.S. One was created by the National Institutes of Health and manufactured by Moderna Inc., and the other developed by Pfizer Inc. and Germanys BioNTech.